U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O2
Molecular Weight 400.6371
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CALCIFEDIOL ANHYDROUS

SMILES

C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C

InChI

InChIKey=JWUBBDSIWDLEOM-DTOXIADCSA-N
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H44O2
Molecular Weight 400.6371
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 2
Optical Activity UNSPECIFIED

Calcifediol (25-Hydroxyvitamin D3 or 25-hydroxycholecalciferol) is a biologically active vitamin D3 metabolite. It is concluded that the liver is the major if not the only physiologic site of hydroxylation of vitamin D3 into calcifediol. Calcifediol is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. RAYALDEE (calcifediol) extended-release capsules is indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RAYALDEE

Approved Use

Calcifediol indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL

Launch Date

2016
Primary
CALDEROL

Approved Use

Unknown

Launch Date

1980
Primary
CALDEROL

Approved Use

Unknown

Launch Date

1980
Primary
CALDEROL

Approved Use

Unknown

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73.2 ng/mL
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1704.4 ng × h/mL
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 day
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species.
2011-02-03
Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.
2010-03-30
Functional evolution of the vitamin D and pregnane X receptors.
2007-11-12
Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
2006-08-05
Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells.
2006-04
Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells.
2005-12-30
Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol.
2005-08-01
Overview of general physiologic features and functions of vitamin D.
2004-12
Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients.
2004
De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase.
2003-09-26
Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development.
2002-02-28
A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis.
1999-09-01
Calcidiol and PTH levels in women attending an osteoporosis program.
1999-04
Proteins in the heat shock-70 family specifically bind 25-hydroxyvitamin D3 and 17beta-estradiol.
1998-04
Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte-derived macrophages.
1993-02
1 alpha,25-dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1.
1991-04-30
Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3.
1990-11
The effect of vitamin D status on cutaneous sterologenesis in vivo and in vitro.
1987-09-14
Hypercalcemia in 25 OH D3 treated patients receiving a calcium exchange resin.
1985-06
Tubular aggregates in a case of osteomalacic myopathy due to anticonvulsant drugs.
1984-01-01
Interrelationship of serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D in juvenile renal osteodystrophy after therapy with 25-hydroxyvitamin D3.
1982
Determination of vitamin D and its metabolites in plasma from normal and anephric man.
1979-07-15
Patents

Sample Use Guides

The initial dose of RAYALDEE (calcifediol) extended-release capsules is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment. Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (PTH) 3 months after starting therapy or changing dose. Increase the dose to 60 mcg once daily after 3 months if intact PTH is above the treatment goal. Ensure serum calcium is below 9.8 mg/dL, phosphorus is below 5.5 mg/dL and 25-hydroxyvitamin D is below 100 ng/mL before increasing the dose. Suspend dosing if intact PTH is persistently abnormally low, serum calcium is consistently above the normal range or serum 25­ hydroxyvitamin D is consistently above 100 ng/mL
Route of Administration: Oral
Vitamin D metabolites down-regulated stimulated IL-8 only in those hyperinflammatory monocyte-derived macrophages, and only when used at high doses (>100 nM for Calcifediol).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:36:18 GMT 2025
Edited
by admin
on Mon Mar 31 17:36:18 GMT 2025
Record UNII
T0WXW8F54E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIFEDIOL,ANHYDROUS
VANDF  
Preferred Name English
CALCIFEDIOL ANHYDROUS
Common Name English
CALCIDIOL
Common Name English
CALCIFEDIOL, ANHYDROUS
Common Name English
CALCIFEDIOL [MI]
Common Name English
calcifediol [INN]
Common Name English
CALCIFEDIOL,ANHYDROUS [VANDF]
Common Name English
Classification Tree Code System Code
LOINC 83071-1
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
NDF-RT N0000175908
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
NCI_THESAURUS C39713
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
LOINC 68438-1
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
LOINC 62292-8
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
WHO-ATC A11CC06
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
LOINC 83070-3
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
Code System Code Type Description
DAILYMED
T0WXW8F54E
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
SMS_ID
100000081591
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
INN
3057
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
CHEBI
17933
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
MERCK INDEX
m2911
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB00146
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
PUBCHEM
5283731
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
NCI_THESAURUS
C77155
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
EVMPD
SUB32968
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
ALTERNATIVE
EVMPD
SUB06045MIG
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
EPA CompTox
DTXSID0022721
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
RXCUI
1855064
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
FDA UNII
T0WXW8F54E
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
ECHA (EC/EINECS)
242-990-9
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
CAS
19356-17-3
Created by admin on Mon Mar 31 17:36:18 GMT 2025 , Edited by admin on Mon Mar 31 17:36:18 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
LABELED -> NON-LABELED
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE